Study reveals how specific nasal cells protect against COVID-19 in paediatric patients
The findings suggest why children tend to experience milder symptoms compared to older adults
Read Moreby Jen Brogan | Apr 17, 2024 | News | 0
The findings suggest why children tend to experience milder symptoms compared to older adults
Read Moreby Jen Brogan | Mar 1, 2024 | News | 0
Different factors, such as illness duration and virus variant, impacted patients cognitive abilities
Read Moreby Jen Brogan | Feb 8, 2024 | News | 0
The committee has advised that the vaccine should be given to those at the highest risk
Read Moreby Jen Brogan | Feb 2, 2024 | News | 0
Dopamine neuron senescence is a hallmark of Parkinson’s disease
Read Moreby Selina McKee | Dec 8, 2020 | News | 0
A 90 year-old woman in Coventry has become the first person in the UK to be given the vaccine
Read Moreby Selina McKee | Nov 16, 2020 | News | 0
The funds will help expand the scale of SARS-CoV-2 virus sequencing in the hope of revealing new opportunities for intervention
Read Moreby Selina McKee | Sep 4, 2020 | News | 0
The findings have validated confidence in the experimental vaccine, the firm noted
Read Moreby Selina McKee | Aug 27, 2020 | News | 0
It is hoped that the vaccine will generate protection not only against SARS-CoV-2, but also against new strains of coronavirus that may arise in the future
Read Moreby Selina McKee | Jul 31, 2020 | News | 0
The patch will be tested to deliver a vaccine dose via the skin, as well as achieve a simple and secure disposal process to enable at-home use.
Read Moreby Selina McKee | Jul 31, 2020 | News | 0
The trial will enrol patients with mild symptoms of SARS-CoV-2 infection to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of CT-P59
Read Moreby Selina McKee | Jul 28, 2020 | News | 0
The companies have started a global pivotal Phase II/III safety and efficacy study
Read Moreby Selina McKee | Jul 14, 2020 | News | 0
The mRNA-based vaccines are currently being evaluated in Phase I/II clinical trials in Germany and the US
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479